spesolimab
Jump to navigation
Jump to search
Indications
- treatment of generalized pustular psoriasis (investigational)
- reduces risk of pustular psoriasis flares[3]
Dosage
- a single 900 mg intravenous dose
Adverse effects
Mechanism of action
- pharmaceutical monoclonal antibody that inhibits IL-36
More general terms
References
- ↑ Bankhead C Dramatic Improvement in Generalized Pustular Psoriasis With IL-36 Inhibitor. Complete clearance of pustules in half of patients in 1 week with spesolimab. MedPage Today December 23, 2021 https://www.medpagetoday.com/dermatology/psoriasis/96365
- ↑ Bachelez H, MChoon SE, Marrakchi S et al Trial of Spesolimab for Generalized Pustular Psoriasis. N Engl J Med 2021; 385:2431-2440 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34936739 https://www.nejm.org/doi/full/10.1056/NEJMoa2111563
- ↑ 3.0 3.1 Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023 Sep 19:S0140-6736(23)01378-8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37738999 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01378-8/fulltext